No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Formycon and MS Pharma Ink Exclusive Deal for Biosimilar Pembrolizumab in MENA Region
On 4 December 2025, Formycon and MS Pharma announced that they have entered into an exclusive licensing and supply agreement for the commercialisation of FYB206, biosimilar to MSD’s Keytruda® (pembrolizumab) in the MENA region.